COMPANY UPDATE July 2016 Forward-Looking Statement Certain - - PowerPoint PPT Presentation

company update
SMART_READER_LITE
LIVE PREVIEW

COMPANY UPDATE July 2016 Forward-Looking Statement Certain - - PowerPoint PPT Presentation

COMPANY UPDATE July 2016 Forward-Looking Statement Certain statements made in this presentation are forward-looking statements and are based on Immurons current expectations, estimates and projections. Words such as anticipates,


slide-1
SLIDE 1

COMPANY UPDATE

July 2016

slide-2
SLIDE 2

Forward-Looking Statement

Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercializing

  • technology. As a result, actual results could materially differ from those expressed or forecasted in

the forward-looking statements. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

2

slide-3
SLIDE 3

Immuron Limited

1H 2016 Developments

3

Company Overview and Pipeline 1H 2016 Developments Upcoming Milestones Summary

slide-4
SLIDE 4

Immuron Limited

Introduction

4

  • Clinical stage biopharmaceutical company focused on oral immunotherapies for

the treatment of inflammatory and gut mediated diseases

  • Strong platform technology (dairy-derived antibodies); wide applicability/low cost
  • Validations: Product approved and launched; US NIH fully funding Phase II studies (ASH)
  • Lead asset IMM-124E targeting fatty liver diseases (NASH / ASH)
  • Targeting LPS endotoxins, a key disease mediator, and up-regulation of suppressor T-Cells
  • Early studies have shown evidence of anti-inflammatory effects + prevention of fibrosis
  • Potential exist to expand the use of IMM-124E in other indications such as diabetes
  • NASH represents a blockbuster opportunity. Large and growing market ($35B-$40B

by 2030) driven by obesity epidemic. No approved drugs. High BD activity

  • Second key asset is IMM-529 which is targeting C-Difficile. This is a bacterial

infection for which Immuron could get orphan drug designation from the FDA

  • Generating growing revenues from OTC products (FY2015: $1.1M)
  • Experienced management team and strong support from KOLs
slide-5
SLIDE 5

5

Platform Overview

Oral Immunotherapy - A Disruptive Technology

Disease Specific Antibodies Induction

  • f

regulatory T-cells

  • Reduces systemic

inflammation

  • Lowers organ injury
  • Not associated with general

immune suppression

  • No risks of severe infection
  • r malignancy
  • Easily tolerated by patients

Vaccines Are Developed Antibodies Are Harvested from Colostrum Bovine adjuvants IgG (IgG1) Broad Therapeutic Effect Clearance of Targeted Pathogens

1 2 3

+

+

Can create therapeutics targeting any microbiome signature(s) Clinical supplies for new therapeutics can be ready for trials in as little as 6 months Extended market protection (regulated as biologics)

slide-6
SLIDE 6

Pipeline

Clinical Assets Targeting Blockbuster Indications

6

New trials since last update (Nov. 2015)

Pre-Clin Phase 1 Phase 2 Phase 3 Market NASH ASH Pediatric NASH IMM-529 Anti-Infective C-Difficile (Orphan) IMM-124E Anti- Inflammatory Colitis TBD Anti-Infective US Army / Shigella IMM-124E / TBD Microbiota Autism Travelan / Protectyn OTC Traveler's Diarrhea / Gut Dysbiosis IMM-124E Immuno- Modulation

(NIH Trial) (NIH Trial)

slide-7
SLIDE 7

Dr Arun Sanyal (MD) – University of Virginia. Professor of Medicine and Former Chairman of the Division of

Gastroenterology, Hepatology and Nutrition, VCU Medical Center. Dr Sanyal is an internationally renowned expert in liver

  • diseases. He is a former President of the AASLD (American Association for the Study of Liver Diseases) and is the current

Chair of the Liver Study Section at the NIH.

Dr Stephen Harrison (MD) – Professor of Medicine, Uniformed Services University of the Health Sciences, Bethesda,

Maryland; Physician, San Antonio Military Medical Center, Fort Sam Houston, San Antonio, Texas. Chief of Residents, Internal Medicine, Brooke US Army Medical Center. Dr. Harrison is an internationally renowned expert in NASH and his group has published seminal work on many aspects in the field. Dr Harrison is the Principal Investigator of Galectin’s GR-MD-02’s Phase II trial and hold's key roles in other leading clinical NASH studies.

Dr Manal Abdelmalek (MD) – Duke University Medical Center. Dr Abdelmalek is Associate Professor of Medicine at

Duke Medical University Medical Center, Division of Gastroenterology & Hepatology, Section of Hepatobiliary Diseases & Liver

  • Transplantation. Dr Abdelmalek is a leading investigator in the field of NASH.

Dr Gerhard Rogler (MD, PhD) – Zurich University. Dr Rogler is the Chairman of the Scientific Advisory Board of the

University of Zurich and Professor of Gastroenterology and Hepatology and Consultant Gastroenterologist at the Division of Gastroenterology & Hepatology, Department of Medicine, Zürich University Hospital, Switzerland. Prof. Rogler is a leader in the field of Colitis and has authored approximately 200 original peer-reviewed articles.

Dr Miriam Vos (MD) – Emory University. Dr Vos is an associate professor of pediatrics at the Emory University School of

Medicine, and an attending Hepatologist at Children’s Healthcare of Atlanta. She specializes in the treatment of gastrointestinal disease in children as well as fatty liver disease and obesity. Dr. Vos is also the author of The No-Diet Obesity Solution for Kids.

  • Dr. Dena Lyras (PhD) – Monash University. Dr Lyras is associate professor at Monash University, is one of the world’s

leading expert in C-Dfficile. Dr Lyras has spent her research career developing world-leading knowledge of C-Difficile. She was the lead author of a seminal study published in Nature in 2009, which shed new light on the essential role specific toxins play in causing disease, a discovery that disproved prevailing opinion.

Stellar KOL Support

Principal Investigators & Scientific Advisory Board

7

slide-8
SLIDE 8

Immuron Limited

1H 2016 Developments

8

Company Overview and Pipeline 1H 2016 Developments Upcoming Milestones Summary

slide-9
SLIDE 9

9

1H2016 Developments

Clinical Assets – Fatty Liver Programs NASH 50% recruitment milestones met in NASH Phase 2 (May 2016)

1

Pediatric NASH Initiation of Pediatric NASH study (3Q 2016)

2

Immuron’s NASH Portfolio: (1) Phase 2 in NASH; (2) Phase in ASH and now (3) Phase 2 in Pediatric NASH

slide-10
SLIDE 10

10

1H2016 Developments

Clinical Assets – C-Difficile C-Difficile IMM-529 reports highly successful pre-clinical data (January 2016)

3

Strongly differentiated and unique triple action mechanism

slide-11
SLIDE 11

11

0 .0 0 .5 1 .0 1 .5 2 .0 2 .5 3 .0 3 .5 4 .0 2 0 4 0 6 0 8 0 1 0 0

S u rv iv a l

h o u rs p o s t in fe c tio n P e rc e n t s u rv iv a l U n in fe c te d , N o tre a tm e n t In fe c te d , N o tre a tm e n t In fe c te d , N o n -im m u n e Ig G tre a tm e n t In fe c te d , IM M -5 2 9 tre a tm e n t In fe c te d , V a n c o m y c in tre a tm e n t 1 2 3 4 2 0 4 0 6 0 8 0 1 0 0 D a y s p o s t in fe c tio n P e rc e n t s u rv iv a l

S u rv iv a l

In fe c te d , N o tre a tm e n t In fe c te d , N o n -im m u n e Ig G tre a tm e n t In fe c te d , IM M -5 2 9 tre a tm e n t In fe c te d , V a n c o m y c in tre a tm e n t U n in fe c te d , N o tre a tm e n t

2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 1 1 0

S u rv iv a l

D a y s a fte r v a n c o m y c in tre a tm e n t c e a s e d P e rc e n t s u rv iv a l

In fe c te d + S O C In fe c te d + S O C + IM M -5 2 9

**

p=0.0027

IMM-529

Results of Pre-Clinical Study

All studies statistically significant Demonstrated 80% efficacy without use

  • f antibiotics

Demonstrated ~90% survival rate vs. 22% survival rate in control group Potentially only therapeutic (approved or in development) that can treat all phases

  • f the disease:

(1) Prophylaxis (2) Treatment (3) Recurrence Demonstrated 80% efficacy without use

  • f antibiotics

Prevention Studies Treatment Studies Relapse Studies

slide-12
SLIDE 12

12

IMM-529

Unique MOA in CDI

Heat, ethanol & UV

  • resistant. Survive gastric

acid, adhere to cells in the colon & germinate

Spores – Infectious Particles

IMM-529 antibodies bind to surface antigens on spores & prevent adheres to host cells & limit germination.

Vegetative Cells

Fimbriae & other surface layer proteins (SLP) contribute to bacterial

  • colonization. Fimbriae are

used to adhere to other bacteria & to host cells and isone of the primary mechanisms of virulence IMM-529 antibodies bind to SLP on vegetative cells & limit colonization.

Toxin B

IMM-529 antibodies neutralise toxin B, inhibiting toxin mediated epithelial cell apoptosis & limit toxin translocation into the systemic circulation & inflammatory cascades Toxin B is essential for

  • virulence. Toxin B disrupt

the cytoskeleton and tight junctions of intestinal epithelial cells

slide-13
SLIDE 13

13

1H2016 Developments

Clinical Assets – Other Colitis Start of Pre-Clinical Programs (February 2016)

4

Expansion and validation of Immuron’s Technology Shigella Vaccine Collaboration with the US Army (June 2016)

5

Autism In collaboration with leading Australian institutions (July 2016)

6

slide-14
SLIDE 14

14

1H2016 Developments

OTC Products US Additions of multiple customers

1

Expansion of retail and distribution footprint

slide-15
SLIDE 15

15

1H2016 Developments

OTC Products (continued) US Multiple PR Exposure (FOX, ABC, NBC, etc.)

2

PR driving growing brand recognition in the US

slide-16
SLIDE 16

16

1H2016 Developments

OTC Products (continued) China Launch of Travelan and Protectyn in China (June 2016)

3

Partnership with JD.com/QBID opens up direct-to-consumer e- commerce channels

slide-17
SLIDE 17

Immuron Limited

1H 2016 Developments

17

Company Overview and Pipeline 1H 2016 Developments Upcoming Milestones Summary

slide-18
SLIDE 18

Key Milestones

Near Term and Long Term Milestones

18

Milestones Timing OTC Products

  • Continued

Expansion (New Territory and Sales Growth) Ongoing C-DIFFICILE

  • Orphan

Indication Filling 3Q2016 Pediatric NASH

  • Study

Initiation 3Q2016 C-DIFFICILE

  • Manufacturing
  • f

Clinical Supplies Completed 3Q2016 C-DIFFICILE

  • Initiation
  • f

Phase 1 4Q2016 NASH

  • Interim

Results 4Q2016 NASH

  • End
  • f

recruitment 4Q2016 C-DIFFICILE

  • Orphan

Indication Granted 4Q2016 NASH

  • Top

Line Phase II Mid-2017 COLITIS

  • Results
  • f

Pre-clinical Studies 2Q2017 C-DIFFICILE

  • Phase

1 Results 4Q2017 ASH

  • Top

Line Phase 2 1H2018

slide-19
SLIDE 19

Immuron Limited

1H 2016 Developments

19

Company Overview and Pipeline 1H 2016 Developments Upcoming Milestones Summary

slide-20
SLIDE 20

Immuron Limited

Investment Highlights

  • Strong Platform – Product already launched; NIH sponsored trials; Support

from leading KOLs

  • Strong Pipeline with Significant Upside – Two Phase II clinical trials with

differentiated profiles in multi-billion market (Fatty liver disease - NASH/ASH)

  • NASH: Phase II results - Mid-2017
  • ASH: Phase II results - 2018; 100% funded by NIH
  • Pediatric NASH
  • C-difficile: Phase 1 results – Mid-2017
  • US Army Collaboration
  • Generating Growing Revenues from Marketed OTC Products – Targeting

WW $1.8M+ in 2016E; $3M-5M in 2017E; $30M/year peak revenues

  • De-Risked Value Proposition – Significant upside from clinical assets,

coupled with growing revenues from OTC business

  • Strong newsflow expected over the next 6-12 months
  • Success in clinic could create licensing/M&A opportunity

20

slide-21
SLIDE 21

THANK YOU